Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 0.99 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.99 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.99 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.99 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.99 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | ABL1 | P00519 | 1/20 | 0.99 |
| ▸ | INSR | P06213 | 1/20 | 0.99 |
| ▸ | RET | P07949 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.99 |
| ▸ | SRC | P12931 | 1/20 | 0.99 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.99 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.99 |
| ▸ | CDK2 | P24941 | 1/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL29464189 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL8100 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL16766960 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29351024 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2505075 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL15971863 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2501563 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3637153 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232064 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232460 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266773-B1 | PROCESS FOR THE PREPARATION OF LAPATINIB DITOSYLATE MONOHYDRATE BY MEANS OF AN IMPROVED CRYSTALLIZATION PROCEDURE | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2018-04-11 | — | — | EP | claimed |
| EP-2572199-B1 | COMBINATION | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | claimed |
| EP-1871347-B1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2550269-B1 | PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB | SCINOPHARM TAIWAN LTD (TW) | 2016-03-23 | — | — | EP | claimed |
| EP-2754662-B1 | Efficient process for the preparation of Lapatinib and salts thereof by means of new intermediates | ITALIANA SINT SPA (IT) | 2015-07-22 | — | — | EP | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| CN-113827596-B | Application of lapatinib and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus drugs | 武汉市金银潭医院(武汉市传染病医院) | 2022-09-09 | — | — | CN | disclosed |
| CN-113827596-A | Application of lapatinib and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus drugs | 武汉市金银潭医院(武汉市传染病医院) | 2021-12-24 | — | — | CN | disclosed |
| EP-3846787-A1 | NOVEL COMPOSITION OF LAPATINIB OF ORAL SOLID DOSAGE FORM AND METHOD OF MANUFACTURING THEREOF | BDR Pharmaceuticals International Private Limited (IN) | 2021-07-14 | — | — | EP | disclosed |
| US-9606089-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20150260696-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | ITALIANA SINT SPA (IT) | 2015-09-17 | — | — | US | disclosed |
| US-8927558-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| EP-2489661-B1 | Impurity of lapatinib and salts thereof | ITALIANA SINT SPA (IT) | 2013-11-13 | — | — | EP | disclosed |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | LEO OSPREY LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| EP-1792902-A1 | Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes | GLAXO GROUP LIMITED (GB) | 2007-06-06 | — | — | EP | disclosed |
| EP-1294715-B1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-7157466-B2 | Quinazoline ditosylate salt compounds | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-02 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1294715-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.